Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New HIV Study Shows That Large Numbers Of Women And People Of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies
Data from a historic HIV study demonstrate that it is possible to recruit large numbers of women, African Americans and Latinos into U.S.-based HIV-1 treatment studies. The study, known as GRACE, is the largest study to date in treatment-experienced adult women with HIV-1 to examine gender and race differences in response to an HIV-1 therapy -- PREZISTA(R) (darunavir) coadministered with ritonavir as part of combination therapy. GRACE findings were presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa.

Smoking Ban 'Has Potential For Positive Changes In Mental Health Units'
New research published in the June issue of the British Journal of Psychiatry, shows most mental health settings in England have faced challenges in introducing smoke-free policies.
News of the day
Stanford Scientists Discover Bladder Cancer Stem Cell
Researchers at Stanford"s School of Medicine have identified the first human bladder cancer stem cell and revealed how it works to escape the body"s natural defenses.
Public Health

Ancora Pharmaceuticals Awarded National Institute Of Health Grant For Continued Malaria Vaccine Research

With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA). The $530,000 Phase I SBIR grant is the third NIH grant Ancora has received. In 2005, the pharmaceutical company was awarded a $3.3 million grant from NIH to develop their current cerebral malaria vaccine candidate. Scientific evidence indicates that severe malarial disease results from the downstream effects of a toxin generated by the malaria parasite. This toxin gives rise to the same clinical manifestations observed in both CM and SMA, leading to the possibility that Ancora"s first vaccine candidate could be successfully used for both. Malaria afflicts up to ten percent of the global population resulting in between two and three million deaths per year. Because of global warming, the World Health Organization (WHO) has predicted that 50 percent of the population will be at risk of this disease by 2010. This latest grant demonstrates NIH"s continued confidence in Ancora"s ability to create cost-effective vaccines utilizing carbohydrate synthesis. The company"s breakthrough method of producing synthetic carbohydrates allows for approaches to bacterial, parasitic, and viral infectious diseases previously unattainable. Ancora Pharmaceuticals is a private venture-backed biopharmaceutical company based in Medford, Massachusetts focused on developing immune system modulation therapeutics using synthetic carbohydrates. Ancora"s automated carbohydrate synthesizer is internationally recognized as the most advanced in the world. Synthetic carbohydrate therapeutics represents an untapped opportunity within the pharmaceutical industry to develop promising vaccines against some of today"s worst infectious diseases. Ancora Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009